ICER Faces New Foe As Patient, Disability Alliance Takes Aims At Reports On Mayzent, Spravato
Groups oppose use of quality-adjusted life year metric, noting ICER’s work is becoming more influential among payers. However, patient advocates do not suggest a uniform methodological alternative.
You may also be interested in...
Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.
If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the ﬁrst new mechanism of action in 30 years to treat major depressive disorder.
Program would use cost per QALY determinations by the Institute for Clinical and Economic Review.